Search 

PledPharma is a Swedish specialty pharma company that develops a new medicine, PledOx®, for prevention of the severe side effects that patients develop as a consequence of chemotherapy treatment of cancer. Many times the treatment cannot be carried out as planned due to very difficult side effects. The current market for supportive cancer care is some SEK 72 billion. PledOx is a medicine within the patent protected substance class PLED, which protects the body’s normal cells against oxidative stress. Oxidative stress is a condition where an overabundance of harmful oxygen molecules (free oxygen radicals) has been formed. We are also evaluating opportunities with PLED substances for other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For more information, please visit www.pledpharma.se

The PROTAGEN GROUP is a leading provider of solutions for the

Pharmaceutical and Biotech industries, supporting drug development towards

personalized medicines and GMP compliant protein characterization services

of outstanding quality.

The PROTAGEN GROUP consists of PROTAGEN AG with a clear focus on

diagnostics, and PROTAGEN Protein Services GmbH (PPS) providing GMP

compliant protein analysis.

PROTAGEN AG has developed the proprietary UNIarray® platform to support

patient stratification and the development of Companion Diagnostics (CDx)

using the diagnostic power of autoantibody signatures in blood. We combine

our outstanding know-how in biostatistics and expertise in Protein arrays and

Luminex technology for the development of novel diagnostic assays. Our R&D

focus is on chronic diseases, e.g. neurodegenerative disorders, endometriosis,

autoimmune diseases such as Rheumatoid Arthritis, Systemic Lupus

Erythematosus and Multiple Sclerosis as well as selected cancer indications,

e.g. Prostate-, Breast-, Ovarian-, Colon- and Pancreatic Cancer.

PROTAGEN Protein Services GmbH (PPS)

is a reliable partner for GMP compliant characterization of biotherapeutics

(NBEs) and biosimilar comparability, including stability and release testing.

PPS combines unique expertise in bioinformatics for protein mass spectrometry

with a long track record in protein chemistry and protein analytics in order to

provide the best quality available. In addition, we provide customer support for

all relevant regulatory issues to match with current regulatory requirements

(FDA, EMA, KFDA) for protein drugs.

RECARDIO is an Austrian based life science company founded in 2011. It is focusing on regenerative therapeutic modalities for the treatment of cardiovascular diseases. After establishing proof-of-principle in vivo, it is developing multiple therapeutic leads as the future regenerative medication for patients with various cardiovascular diseases, with the potential of improving their cardiac function, quality of life and survival.  

Scancell is an AIM listed UK based company developing novel therapeutic vaccines for the treatment of cancer based on its groundbreaking ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is a DNA vaccine being developed for the treatment of melanoma and is in Phase 2 clinical trials.

 

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

 

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

 

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

 

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Moditope™ platform could have a profound effect on the way that cancer vaccines are developed.

Shield Therapeutics is an independent specialty pharmaceutical company, founded in 2008 with operations in Europe & US. Focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need Shield is led by Carl Sterritt, Chief Executive Officer, an experienced senior pharmaceutical executive with a track record of successful development and commercialisation of pharmaceuticals Shield has successfully raised ~$34m to fund the development of ST10 and PT20 (developed through Phosphate Therapeutics) Lead asset – ST10: Simplifying iron replacement therapy ·         Novel oral iron-based therapy with strong IPR ·         Potential to be the first simple effective oral therapy for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) and non-dialysis dependant chronic kidney disease (CKD) ·         Currently in Phase III trials in patients with IDA in IBD ·         Results are expected to form the basis of a marketing authorisation application (“MAA”) in 2013.  If approved, product commercialisation could commence in 2014 ·         CKD-IDA trials to follow in 2012-2013 ·         Targets potential addressable market of $5bn, with immediate IV market currently reaching  >$1bn pa   PT20: for the treatment of hyperphosphataemia ·         Novel phosphate binder to treat hyperphosphataemia in patients with pre-dialysis and dialysis-dependent CKD ·         In-licensed from Medical Research Council - agreement signed in Q3-11 ·         Early data from in vitro and in vivo trials suggests higher specificity and efficacy than current market leaders and favourable opinion received from UK-MHRA for progression to Phase II clinical trials ·         Approximately 90% of patients with kidney failure require phosphate binder therapy at some point ·         Current market size >$1bn/yr  

SOM Biotech has developed a proprietary Drug Repurposing technology platform for discovery of new therapeutic indications for given drugs, which we are offering to partners for expanding their drug pipeline.

During the last 34 months we have validated 41 new indications, with 18 positive hits (43%), of which 3 cover clear medical need indications:

SOM0777 for the treatment of Glioma, already licensed to Argon Pharma and Draconis Pharma.

SOM0226 for the treatment of TTR-Amyloidosis. Orphan Disease. Phase II planned for 1Q 2013.

SOM0606 for the topical treatment of Psoriasis, in preclinical development. Phase II expected for 4Q 2013.

25 more repurposing programs per year are running to file the advanced company pipeline.

SuppreMol, a privately held biopharmaceutical Company, is developing novel proteins to treat autoimmune diseases. SuppreMol has developed a novel therapeutic concept for the treatment of autoimmune diseases that relies on naturally produced Fc gamma receptors (FcγRs). The Company was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry.

The Company is developing SM101 for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) in Phase II clinical trials. SM101 is designed to be a specific, early onset, long lasting and well tolerated treatment for autoimmune diseases such as ITP, SLE, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS).

Further building its platform of selective immunoregulators, SuppreMol is working on antibody programs targeting Fc receptors and other immunomodulatory molecules for alternative treatment strategies in autoimmune conditions.